Losartan May Not Prevent Vestibular Schwannoma Growth or Related Hearing Loss During Observation
- 1 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 45 (6) , 690-695
Abstract
Objective: To evaluate the impact of losartan on vestibular schwannoma (VS) growth and related hearing loss during observation. Study design: Retrospective cohort study Setting: Tertiary referral center Patients: Sporadic VS patients undergoing initial observation with at least two magnetic resonance imaging and audiologic examinations. Intervention: Losartan Main Outcome Measures: Endpoints included VS growth, quantitative audiologic changes, survival free of tumor growth, and survival free of nonserviceable hearing. Patient characteristics and endpoints were compared by losartan use. Results: Seventy-nine patients were included, of which 33% were taking losartan. Tumor growth was observed in 50% of patients in the losartan group and 36% in the non-losartan group (p = 0.329). Survival analysis failed to show a significant difference in the hazard rate of VS growth between groups (hazard ratio, 1.38; 95% confidence interval, 0.70–2.70; p = 0.346). Throughout observation, mean decreases in normalized pure-tone average were 5.5 and 9.3 dB in the losartan and non-losartan groups, respectively (p = 0.908). Mean decreases in normalized word recognition score were 11.0 and 16.6% in the losartan and non-losartan groups, respectively (p = 0.757). Nonserviceable hearing developed in 19% of patients in the losartan group and 28% in the non-losartan group (p = 0.734). Survival analysis did not demonstrate a significant difference in the hazard rate of developing nonserviceable hearing between groups (hazard ratio, 1.71; 95% confidence interval, 0.56–5.21; p = 0.337). Conclusions: Losartan use may not reduce the risk of VS growth or hearing loss during observation. A randomized trial would be ideal to further identify the true effect on growth and hearing.Keywords
This publication has 31 references indexed in Scilit:
- Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport miceThe Journal of Pathology, 2023
- The Effect of Metformin on Vestibular Schwannoma Growth: A Systematic Review and Meta‐analysisThe Laryngoscope, 2023
- Association between hypertension, dyslipidemia, and diabetes and prevalence of hearing impairment in JapanHypertension Research, 2020
- Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomesJournal of Neuro-Oncology, 2019
- Probable Association of Hearing Loss, Hypertension and Diabetes Mellitus in the ElderlyInternational Archives of Otorhinolaryngology, 2017
- The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannomaJournal of Neuro-Oncology, 2017
- A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomasJournal of Neuro-Oncology, 2017
- Zucker diabetic fatty rats, a model for type 2 diabetes, develop an inner ear dysfunction that can be attenuated by losartan treatmentCell and tissue research, 2015
- Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomasJournal of Neuro-Oncology, 2015
- Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma)∗Otolaryngology–Head and Neck Surgery, 1995